This meta-analysis synthesized data from 14 trials involving 580 stroke patients to evaluate the efficacy of repetitive peripheral magnetic stimulation (rPMS) for upper extremity motor dysfunction and spasticity. The analysis identified a significant therapeutic effect for FMA-UE score improvement (SMD = 0.91, 95% CI 0.31 to 1.51, p = 0.003) and a significant reduction in spasticity (SMD = -1.15, 95% CI -1.80 to -0.49, p = 0.0006).
A dose-response analysis identified an inverted U-shaped curve for certain parameters. A frequency of 10 Hz achieved peak gain in FMA-UE scores (peak gain: 13.82 points, 95% CI 9.65 to 18.00). Regarding stimulation targets, neural-targeted stimulation demonstrated superiority over muscle-targeted approaches in the subacute phase (SMD 0.81 vs 0.47, p = 0.006).
Other analyzed parameters included a plateau effect for intensity at 20 to 55% maximum stimulator output (MSO), a suggested optimal duration of 10 to 20 minutes per session, and a treatment course of 21 days or more. However, the authors did not report specific limitations or adverse event data in the provided synthesis.
Clinically, these findings suggest that rPMS parameters may be optimized using low frequency (≤20 Hz), moderate-to-low intensity (20 to 55% MSO), and an extended treatment course (≥21 days), particularly when utilizing neural-targeted protocols during the subacute phase of stroke recovery.
View Original Abstract ↓
BackgroundRepetitive peripheral magnetic stimulation (rPMS), a representative non-invasive neuromodulation technique, is widely utilized for the recovery of motor dysfunction following stroke. Although its clinical efficacy has been confirmed, discrepancies among studies and the optimal rPMS stimulation parameters remain unclear. This study aims to systematically analyze and quantitatively evaluate the optimal stimulation parameters using rPMS parameter subgroups extracted from existing studies.MethodsConducted in accordance with PRISMA guidelines, this study searched for research related to rPMS and the Fugl-Meyer Assessment for Upper Extremity (FMA-UE) in stroke patients. A systematic review and meta-analysis of the aggregated studies were then performed. Furthermore, a robust error meta-regression (REMR) model was employed to explore the non-linear dose-response relationship between rPMS stimulation parameters (frequency, intensity, duration, and treatment days) and FMA-UE scores.ResultsA total of 14 trials (n = 580) were included. The results indicated that rPMS yielded a significant therapeutic effect on FMA-UE score improvement (SMD = 0.91, 95% CI 0.31–1.51; p = 0.003) and spasticity reduction (SMD = −1.15, 95% CI − 1.80 to −0.49; p = 0.0006). Dose-response analysis revealed an inverted U-shaped curve for both frequency and duration: the greatest clinical benefits were achieved with optimal stimulation at 10 Hz (peak gain: 13.82 points, 95% CI 9.65–18.00), 10–20 min per session, a plateau effect at 20–55% maximum stimulator output (MSO), and a treatment course of ≥21 days. During the subacute stroke window (14 days to 6 months), neural-targeted stimulation (e.g., brachial plexus, radial nerve) demonstrated superiority over muscle-targeted approaches (SMD = 0.81 vs. 0.47; p = 0.006).ConclusionUnder optimal parameter windows, the therapeutic mechanism of rPMS may be associated with triggering homeostatic plasticity and beta-band corticomuscular coherence. The greatest benefits are obtained particularly with neural-targeted protocols during the subacute phase of stroke, utilizing low frequency (≤20 Hz), moderate-to-low intensity (20–55% MSO), and an extended treatment course (≥21 days). In conclusion, current evidence provides a novel scientific basis and clinical reference for the application of rPMS in stroke rehabilitation.